Drugs / CD34+ hematopoietic stem cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02986698 | Oct 2017 → Apr 2024 | alpha thalassemia spectrum, congenital anemia, hydrops fetalis | University of California, San Francisco | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD34+ hematopoietic stem cells | “The cellular product is: Semi-allogeneic, Related, Maternal Bone Marrow-Derived, Miltenyi CliniMACS Plus enriched CD34+ hematopoietic stem cells administered in utero at a dose...” NCT02986698 ↗ |
| Modality | Cell therapy | “in utero hematopoietic stem cell transplantation” NCT02986698 ↗ |
| Route | Intravenous | “Stem cells will be administered immediately before the red blood cells intravenously via the umbilical vein during the clinically indicated IUT.” NCT02986698 ↗ |